Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Pence says he will not endorse former boss Trump in 2024 US electionTruancy: Why it matters, what the law says and what is being done about itMinistry of Health 'taking the time to get it right' on puberty blockersKaimanawa wild horses: Group re2 Walk and Cycle Conference: Government's transport approach a 'head wind' to progressTwo in custody after armed police swarm Auckland suburbKaimanawa wild horses: Group rePort Hills: Fire crews sent to investigate after reports of smokeHuman Rights Commission advises caution over boot campsMinistry of Health 'taking the time to get it right' on puberty blockers
2.9629s , 6503.3359375 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Culture Circuit news portal